Please ensure Javascript is enabled for purposes of website accessibility

Why DBV Technologies Jumped Higher Today

By Brian Orelli, PhD - Feb 14, 2018 at 1:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA is "supporting" the biotech submitting a marketing application for Viaskin Peanut, but how strong that support is remains to be seen.

What happened

DBV Technologies (DBVT 7.06%) is up 24% at 12:31 p.m. EST after announcing that it's worked out the context for submitting the marketing application for its peanut allergy treatment, Viaskin Peanut, with the Food and Drug Administration.

So what

Normally, pre-application meetings don't result in double-digit increases for biotechs, but DBV is in a precarious situation.

Viaskin Peanut showed an effect in the phase 3 Pepites trial with 35.3% of patients considered responders after taking Viaskin Peanut for 12 months compared to 13.6% of patients who received a placebo. But the trial technically failed because the difference in the lower end of the 95% confidence interval -- a statistical measure -- failed to meet the 15% threshold.

A child sticking their hand out to refuse a bowl of peanuts.

Image source: Getty Images.

DBV's disclosure implies that the FDA may be giving the company a pass on not meeting the confidence interval threshold. DBV Chairman and CEO Pierre-Henri Benhamou characterized the feedback from the FDA as "supporting submission" of the marketing application, but without seeing the written response to DBV's meeting package, it's hard to know if the FDA is giving strong support.

Now what

DBV plans to file the application in the second half of 2018. An acceptance of the application by the FDA will be the first hurdle, but it probably won't be until an FDA advisory committee meeting -- assuming there is one -- when investors will get a true sense of the agency's feelings about DBV's data package.

In the meantime, DBV investors should be watching Aimmune Therapeutics (AIMT), which is scheduled to release top-line data from the phase 3 Palisade trial testing its peanut allergy therapy AR101 this month. Aimmune plans to present the full data at the 2018 American Academy of Allergy, Asthma & Immunology–World Allergy Organization Joint Congress next month.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

DBV Technologies S.A. Stock Quote
DBV Technologies S.A.
DBVT
$1.53 (7.06%) $0.10
Aimmune Therapeutics, Inc. Stock Quote
Aimmune Therapeutics, Inc.
AIMT

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
344%
 
S&P 500 Returns
120%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.